148 related articles for article (PubMed ID: 20575182)
1. Special report: vaccines for the treatment of prostate cancer.
Technol Eval Cent Assess Program Exec Summ; 2010 Apr; 24(6):1-2. PubMed ID: 20575182
[No Abstract] [Full Text] [Related]
2. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
3. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
Arlen PM; Gulley JL; Tsang KY; Schlom J
Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
[TBL] [Abstract][Full Text] [Related]
4. PSA-based vaccines for the treatment of prostate cancer.
Madan RA; Gulley JL; Arlen PM
Expert Rev Vaccines; 2006 Apr; 5(2):199-209. PubMed ID: 16608420
[TBL] [Abstract][Full Text] [Related]
5. [Vaccine therapy of prostate cancer].
Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
[TBL] [Abstract][Full Text] [Related]
6. Clinical Trials Referral Resource. Trials using tumor vaccines.
Cheson BD; Phillips PH; Sznol M
Oncology (Williston Park); 1997 Jan; 11(1):81-2, 84, 90. PubMed ID: 9115855
[No Abstract] [Full Text] [Related]
7. Immune-based therapies for prostate cancer.
McNeel DG; Malkovsky M
Immunol Lett; 2005 Jan; 96(1):3-9. PubMed ID: 15585302
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer vaccines in clinical trials.
Lubaroff DM
Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic vaccines for prostate cancer: a review of clinical data.
Arlen PM; Gulley JL
Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutics in development for prostate cancer.
Harzstark AL; Small EJ
Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R
Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265
[TBL] [Abstract][Full Text] [Related]
12. Current immunotherapeutic strategies in prostate cancer.
Grosso JF; Drake CG
Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
Stadler WM; Michaelis LC; Ratain MJ
J Clin Oncol; 2005 Nov; 23(31):8124-5; author reply 8125-6. PubMed ID: 16258115
[No Abstract] [Full Text] [Related]
15. Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer.
Lubaroff DM; Konety B; Link BK; Ratliff TL; Madsen T; Shannon M; Ecklund D; Williams RD
Hum Gene Ther; 2006 Feb; 17(2):220-9. PubMed ID: 16454655
[No Abstract] [Full Text] [Related]
16. Concerns about Provenge simmer as CMS ponders coverage.
Goozner M
J Natl Cancer Inst; 2011 Feb; 103(4):288-9. PubMed ID: 21303996
[No Abstract] [Full Text] [Related]
17. Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
Theoret MR; Arlen PM; Pazdur M; Dahut WL; Schlom J; Gulley JL
Clin Genitourin Cancer; 2007 Jun; 5(5):347-50. PubMed ID: 17645835
[No Abstract] [Full Text] [Related]
18. Serum antibodies to blood group A predict survival on PROSTVAC-VF.
Campbell CT; Gulley JL; Oyelaran O; Hodge JW; Schlom J; Gildersleeve JC
Clin Cancer Res; 2013 Mar; 19(5):1290-9. PubMed ID: 23362327
[TBL] [Abstract][Full Text] [Related]
19. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
20. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
Kaufman HL; Wang W; Manola J; DiPaola RS; Ko YJ; Sweeney C; Whiteside TL; Schlom J; Wilding G; Weiner LM
J Clin Oncol; 2004 Jun; 22(11):2122-32. PubMed ID: 15169798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
